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Background: Hyperbilirubinemia is common in neonates, with higher 
prevalence among preterm neonates, which can lead to severe 
hyperbilirubinemia. Assessment of total serum bilirubin (TSB) and the 
use of a transcutaneous bilirubinometry (TcB) are existing methods 
that identify and predict hyperbilirubinemia. This study aimed to 
determine TcB cut-off values during the first day for preterm neonates 
to predict hyperbilirubinemia at 48 and 72 hours. 
Methods: This cohort study was conducted at Dr. Soetomo General 
Hospital from September 2018 to January 2019 a total of 90 neonates 
born ≤35 weeks. They were divided into two groups (Group I: 1000-
1500 grams; Group II: 1501-2000 grams). The bilirubin levels were 
measured on the sternum using TcB at the ages of 12, 24, and 72 hours. 
TSB measurements were taken on the third day or if the TcB level 
reached phototherapy threshold ± 1.24 mg/dL and if TcB showed 
abnormal results (Group I: 5.76-8.24 mg/dL; Group II: 8.76-
11.24 mg/dL). Hyperbilirubinemia was defined as TSB ≥7 mg/dL for 
Group I and >10 mg/dL for Group II. 
Results: In total, 38 Group I neonates and 48 Group II neonates were 
observed. Almost half of the neonates in Group I (45%) suffered from 
hyperbilirubinemia at the age of 48 hours, along with 46% of Group II 
at 72 hours. The best 24-hour-old TcB cut-off values to predict 
hyperbilirubinemia at 48 hours were calculated to be 4.5 mg/dL for 
Group I and 5.8 mg/dL for Group II. The determined 24-hour-old TcB 
value to predict hyperbilirubinemia at 72 hours was 5.15 mg/dL for 
Group II. 
Conclusion: TcB values in the early days of life can be used as 
hyperbilirubinemia predictors on the following days for preterm 
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Hyperbilirubinemia is a common condition occurring in neona-
tal periods1, with a prevalence of around 60% in term neonates 
and 80% in preterm neonates. Preterm neonates have a greater 
risk of severe hyperbilirubinemia, which can lead to encepha-
lopathy2. This condition is preventable if early detection and 
prompt treatment can be arranged and managed correctly1,3,4.
Visual assessment is not reliable especially in the first 
24–48 hours, since only 80% of jaundiced babies can be recog-
nized visually if the bilirubin level reaches > 6 mg/dL5–8. High 
bilirubin levels can be dangerous, since preterm neonates have a 
greater risk of low bilirubin kernicterus2.
Total serum bilirubin (TSB) measurement remains the gold 
standard for diagnosing hyperbilirubinemia. However, the draw-
backs of this procedure are that it is painful, causes stress to the 
neonates, has a higher risk of infection, and requiresa couple 
of hours to obtain the results9–11.
Transcutaneous bilirubinometry (TcB) is a non-invasive pro-
cedure used to identify hyperbilirubinemia. Several studies 
have been conducted to validate TcB to assess whether it can be 
used safely. These studies found that TcB has good correlations 
with TSB. The use of TcB can also reduce the need for blood 
sampling by 41–73%11–13.
Due to the burdens of hyperbilirubinemia, its early detection 
and prediction are crucial. TSB or TcB is recommended to pre-
dict neonatal hyperbilirubinemia for neonates with >35 weeks of 
gestation12,14,15. In a systematic review by Nagar et al.16, most 
of 22 articles studied the accuracy of TcB to estimate TSB, and 
TcB could be used in clinical practice to reduce blood sampling. 
Some studies have used TcB to predict significant hyperbiliru-
binemia in subsequent days, but all of them recruited only late 
preterm and term neonates5,17. For preterm neonates, one study 
was already conducted using TSB measurements at 6–24 hours 
to predict hyperbilirubinemia in the following hours or days4. 
As far as the researchers know, there have been no previous stud-
ies using TcB to predict subsequent, significant hyperbilirubine-
mia for older preterm neonates. Therefore, this study aimedto 
use TcB to predict hyperbilirubinemia in preterm neonates 
to prevent complications since visual assessment is unreliable.
Methods
Study background and ethical approval
This cohort study was conducted in the neonatal intensive 
care unit at Dr Soetomo General Hospital for five months 
(September 2018–January 2019). This study was approved by 
Dr. Soetomo General Hospital Surabaya Ethics Committee (No. 
0586/KEPK/Ix/2018). Parents signed the informed consent form 
after they understood the information. The study size retrieved 
in this research used purposive sampling with inclusion and 
exclusion criteria (a flow diagram is available as Extended data)18,19 
during the research period. The sample size was estimated 
by applying Hulley et al.’s20 formulation, with a confidence 
interval of 95%, a coefficient correlation of 0.84 and a standard 
deviation of 1.84. Therefore, the minimum sample size of 20 
was applied for each group, classified by infants’ body weights. 
Staying in line with the minimum sample size, the samples were 
expanded up to 45 infants for each group, with a total sample 
of 90 infants. However, four datasets were excluded due to 
missing TSB measurement.
Race and thickness of the skin tissue’s melanin layer were 
taken into account as confounding variables, and as variables 
able to change the outcomes of others. Therefore, to control for 
study bias, the subjects addressed for this study were those 
with similar ethnic backgrounds: Malay Mongoloid.
Participant eligibility
The inclusion criteria were: 1) birth at ≤35 weeks of gesta-
tional age with a birth weight < 2000 g, and 2) parental consent 
given by signing a form. The exclusion criteria were: 1) being 
diagnosed with hyperbilirubinemia at the age of 12 hours, 2) hav-
ing any major congenital anomaly, or 3) being discharged from 
hospital at less than three days old. Neonates who received pho-
totherapy before the observation was complete, missed TSB, or 
voluntarily resigned from this study were excluded from the 
study. The recruited subjects were divided into two groups: 
neonates with birth weights of 1001-1500 g (Group I) and 
1501-2000 g (Group II).
Variables
The bilirubin level of each neonate was measured on the sternum 
by TcB (Dräger® Jaundice Meter 105) at 12 hours, 24 hours, 
and 72 hours with ±3 hours tolerance (the TcB measurement 
could be taken within three hours before/after the exact time). 
The TSB measurement was taken for each neonate at the age 
of three days or if the TcB bilirubin level was ≥5.76 (7–1.24) 
mg/dL for Group I and TcB ≥8.76 (10–1.24) mg/dL for Group 
II and it had to be taken within six hours before or after the TcB 
measurement (assumption of TcB standard deviation being 
±1.24 mg/dL). The TSB measurement also had to be taken if 
the TcB measurement showed abnormal results. Hyperbiliru-
binemia was defined as TSB ≥7 mg/dL for preterm neonates 
with birth weights of 1000–1500 g and TSB >10 mg/dL for pre-
term neonates with birth weights of 1501–2000 g as suggested 
by the Kaplan et al., in Martin’s Neonatal-Perinatal Medicine 
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(2011).21 TSB was measured in the central laboratory using 
SIEMENS Dimension® with a modified Doumas22 reference 
method, which is a modification of the diazo method described by 
Jendrassik and Grof in 193823. Internal calibration was completed 
daily, with a quality control printout. The Indonesian External 
Quality Assurance Service performed external quality control.
Statistical analysis
The data was analyzed by Microsoft Office Excel, IBM SPSS 
Statistics Version 21. Receiver operating characteristic (ROC) 
curve analysis was performed to determined the TcB level 
cut-off point to predict hyperbilirubinemia at the age of 48 and 
72 hoursThe specificity, sensitivity, positive predicted value 
(PPV), negative predicted value (NPV), and likelihood ratio 
were calculated.
Results
There were 90 preterm neonates recruited for this study, 40 of 
whom weighed 1000–1500 grams (Group I) and 50 of whom 
weighed 1501–2000 grams (Group II). Only 38 neonates 
in Group I and 48 neonates of Group II were observed until the 
end of the study. Four neonates were excluded from the study 
due to missing TSB results.
Maternal and neonatal characteristics are shown in Table 1. 
For Group I, the mean gestational age of Group I was 32.29 
± 1.84 weeks, with a mean birth weight of 1273.68 ± 177.34 g. 
Meanwhile, for Group II the mean gestational age was 33.69 ± 
1.26 weeks, witha mean birth weight of 1792.70 ± 145.86 g. 
Based on the risk factors of ABO-incompatibility, one subject of 
Group I who suffered hyperbilirubinemia at the age of 48 hours. 
Meanwhile, two subjects in Group II suffered hyperbilirubine-
mia at the age of 48 hours and another two subjects at the age 
of 72 hours. At the end of the observation, the maximum bilirubin 
level was 15.2 mg/dl for Group I and 16.33 mg/dL for Group II. 
Most neonates of Group I (45%) suffered hyperbilirubinemia 
at the age of 48 hours, while most neonates of group II (46%) 
at the age of 72 hours (Figure 1). The TSB means in Group I at 
the ages of 24, 48, and 72 hours were 7.9 mg/dL, 9.16 mg/dL, 
and 9.3 mg/dL respectively, and 11.01 mg/dL, 10.23 mg/dL, 
and 11.04 mg/dL respectively, in Group II.
Using TcB bilirubin levels to predict hyperbilirubinemia at 
the age of 48 hours in Group I preterm neonates
A ROC curve was constructed to determine a hyperbilirubine-
mia threshold based on the data collected. For Group I, the area 
under the curve (AUC) of the TcB bilirubin level at the age of 
12 hours to predict hyperbilirubinemia at the age of 48 hours 
was 0.804 (p = 0.002), with a cut-off point of 2.35 mg/dL (sen-
sitivity: 79.20%;specificity: 71.40%). For TcB bilirubin levels at 
the age of 24 hours to predict hyperbilirubinemia at the age 
of 48 hours, the AUC was 0.771 (p = 0.06), with a cut-off 
point of 4.50mg/dL (sensitivity: 87.50%; specificity: 64.26%) 






Gestational Age (weeks) 
(mean ±SD)
32.29 ± 1.84 33.69 ± 1.26
Mode of delivery 
   -    spontaneous 
   -    c-section 









Maternal Blood Type 
   A 
   B 
   O 














Birth Weight (g) (mean ±SD) 1273.68 ± 177.34 1792.70 ± 145.86
Hematocrit (%) (mean ±SD) 48.04 ± 10.47 46.99± 8.48
Gender 
   Male 








   A 
   B 
   O 











*Descriptive analysis was used. Maternal and neonatal rhesus were positive.
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Figure 1. The proportionof hyperbilirubinemia in preterm neonates.
Figure 2. Transcutaneous bilirubinometry  (TcB)  level  to predict hyperbilirubinemia at  the age of 48 hours. (a) Receiver operating 
characteristic (ROC) curve for TcB at the age of 12 hours to predict hyperbilirubinemia at the age of 48 hours for Group I. (b) ROC curve for 
TcB at the age of 24 hours to predict hyperbilirubinemia at the age of 48 hours for Group I. (c) ROC curve for TcB at the age of 12 hours to 
predict hyperbilirubinemia at the age of 48 hours for Group II. (d) ROC curve for TcB at the age of 24 hours to predict hyperbilirubinemia at 
the age of 48 hours for Group II.
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Using TcB bilirubin levels to predict hyperbilirubinemia at 
the age of 48 hours in Group II preterm neonates
The AUC of TcB bilirubin levels at the age of 12 hours to pre-
dict hyperbilirubinemia at the age of 48 hours for Group II was 
0.658 (p = 0.083), with a cut-off point of 3.05 mg/dL (sensitiv-
ity: 66.7%; specificity: 66.7%). The AUC of TcB bilirubin levels 
at the age of 24 hours was 0.732 (p = 0.011), with a cut-off 
point of 5.80 mg/dL (sensitivity: 80%; specificity: 63.6%). 
(Figure 2c, Figure 2d and Table 3).
Using TcB bilirubin levels to predict hyperbilirubinemia at 
the age of 72 hours in Group I preterm neonates
The TcB bilirubin levels of Group I at the ages of 12, 24, and 
48 hours to predict hyperbilirubinemia at the age of 72 hours 
showed a very weak AUCs, which were 0.243 (p = 0.386), 0.297 
(p = 0.494), 0.500 (p = 1.000), respectively; therefore, no 
cut-off point could be determined.
Using TcB bilirubin levels to predict hyperbilirubinemia at 
the age of 72 hours in Group II preterm neonates
Using the TcB bilirubin levels of Group II at the age of 12 hours 
to predict hyperbilirubinemia at the age of 72 hours showed 
a weak AUC (0.499, p = 0.991) with a cut-off point of 2.65 
mg/dL (sensitivity 60% and specificity 46%). At the age of 
24 hours, the TcB AUC was 0.751 (p = 0.008), with a cut-off 
point of 5.15 mg/dL (sensitivity: 74.3%; specificity: 76.9%). 
Meanwhile, at the age of 48 hours the TcB AUC was 0.731 
(p = 0.015), with a cut-off point of 8.65 mg/dL (sensitivity: 
67.6%; specificity: 61%) (Figures 3a–c and Table 4).
Discussion
This study determined a TcB cut-off value of 4.5 mg/dL at the 
age of 24 hours for Group I (1000–1500 grams) and 5.8 mg/dL 
for Group II (1501–2000 grams) as predictive of hyperbiliru-
binemia at 48 hours. This study could not determine a TcB cut-
off value to predict hyperbilirubinemia at the age of 72 hours for 
Group I as a result of weak correlation. The TcB cut-off value 
of 5.15 mg/dL at the age of 24 hours was determined as the 
best predictor for hyperbilirubinemia at the age of 72 hours 
in Group II. This cut-off level was established with a sensitiv-
ity value ranging from 74.3% to 87.5% at 24 hours after birth. 
Similar studies have already been conducted, but those studies 
recruited only late preterm neonates. Lavanya et al. found that 
TcB values measured in the first 24–48 hours of life can predict 
hyperbilirubinemia at more than 48 hours24. Bansal et al. deter-
mined that TcB values > 4.6 mg/dL at 12–24 hours (sensitivity: 
83.09%; specificity: 87.37%; PPV: 90.4%; NPV: 78.3%) and > 
7.4 mg/dL at the age of 24–48 hours (sensitivity: 93.55%; spe-
cificity: 82.11%; PPV: 81.69%; NPV: 95.35%) are predictors for 
hyperbilirubinemia in the first 48 hours of life5. Other studies 
used TSB values to predict hyperbilirubinemia in the follow-
ing days. Mayer recruited preterm neonates weighing 1000–1500 
grams and determined a capillary TSB value of 3.55 mg/dL 
at the age of 12 hours as the best predictor of significant 
hyperbilirubinemia (sensitivity: 94.4%; PPV: 98.1%; NPV: 40%)4.
Most neonates recruited in this study suffered hyperbilirubine-
mia before the age of 72 hours. This study also showed that 
smaller babies suffered peak incidence earlier (at 48 hours) 
than larger babies (at 72 hours). It shows that that higher birth 
weight has opportunity to be hyperbilirubinemia later than the 
lower birthweight. The lower birthweight has lower threshold 
bilirubin, because they have higher chance to become enceph-
alopathy in lower bilirubin level (high risk infants). The 
younger gestational age and lower birth weight, lead to a higher 
prevalence of infants developing hyperbilirubinemia. It is a 
result of excessive neonatal red cell hepatic and immaturity of 
the gastrointestinal system. Prematurely delivered infants have a 
likelihood of slower maturation of hepatic bilirubin uptake and 
conjugation25,26. Hyperbilirubinemia is more prevalent in preterm 
neonates4,5,24) and is usually more severe and has a longer duration 
compared to that in term neonates4. This is caused by increased 
bilirubin production, decreased bilirubin excretion, increased 
enterohepatic circulation, lower albumin levels and a weak 
albumin-bilirubin bond10,27. Early detection of hyperbilirubine-
mia decreases its mortality and morbidity, and the need for 
reliable methods to predict hyperbilirubinemia is crucial. The 
use of a non-invasive procedure, like TcB, in the first 6–24 hours 
of life is recommended as a marker of bilirubin production28 and 
it can decrease the need for blood sampling29.
In Group I at the ages of 24, 48, and 72 hours, the TSB mean 
values were 7.9, 9.16, and 9.3 mg/dL, respectively; in Group II, 
these values were 11.01, 10.23, and 11.04 mg/dL, respectively. 
This is similar to a previous study that found that TSB mean val-
ues in the first five days of preterm neonates were 10–12 mg/dL21. 
However, this study found that some preterm neonates 







Sn (%) Sp (%) PPV (%) NPV (%) LR
12 hours 
old 2.35 79.2 71.4 82.60 66.67 2.78
24 hours 
old 4.5 87.5 64.3 80.77 64.26 2.45
†Receiver operative characteristic curve analysis was used. Sn: sensitivity; 
Sp: specificity; PPV: positive predictive value; NPV: negative predictive 






Sn (%) Sp (%) PPV (%) NPV (%) LR
12 hours 
old 3.05 66.7 66.7 47.62 81.48 2.00
24 hours 
old 5.85 80 63.6 50.00 87.50 2.19
†Receiver operative characteristic curve analysis was used. Sn: sensitivity; 
Sp: specificity; PPV: positive predictive value; NPV: negative predictive 
value; LR: likelihood ratio.
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Sn (%) Sp (%) PPV (%) NPV (%) LR
12 hours old 2.65 60 46 75.00 30.00 1.11
24 hours old 5.15 74.3 76.9 89.66 52.63 3.22
48 hours old 8.65 67.6 61 82.75 42.10 1.78
†Receiver operative characteristic curve analysis was used. Sn: sensitivity; Sp: 
specificity; PPV: positive predictive value; NPV: negative predictive value; LR: 
likelihood ratio.
Figure 3. Transcutaneous bilirubinometry  (TcB)  level  to predict hyperbilirubinemia at  the age of  72 hours. (a) Receiver operating 
characteristic (ROC) curve for TcB at the age of 12 hours to predict hyperbilirubinemia at the age of 72 hours for Group II. (b) ROC curve for 
TcB at the age of 24 hours to predict hyperbilirubinemia at the age of 72 hours for Group II. (c) ROC curve for TcB at the age of 48 hours to 
predict hyperbilirubinemia at the age of 72 hours for Group II.
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neonates can have high bilirubin levels in the first days of life, 
which can lead to hyperbilirubinemia complications if not rec-
ognized and treated properly. The previous study conducted by 
Bhutani et al., also indicated that neonates who suffered from 
hyperbilirubinemia in the following days had higher percentiles 
on the first day of life30. Therefore, the American Academy of 
Pediatrics recommends routine checks of TSB or TcB along 
with risk factor assessments in the first days of life14.
To the knowledge of the researchers, this was the first study 
conducted to predict significant hyperbilirubinemia in preterm 
neonates weighing 1000–2000 grams using TcB. A limitation of 
the study was that it could not determine TcB cut-off values to 
predict hyperbilirubinemia at the age of 72 hours for preterm 
neonates weighing 1000–1500 grams due to a lack of subjects 
able to complete the study, since most had already developed sig-
nificant hyperbilirubinemia by this time. The mothers’ rhesus blood 
groups and the babies’ G6PD levels were not obtained. 
Hopefully, future similar studies will be able to recruit larger 
populations.
Conclusion
TcB values in the early days of life can be used as a predic-
tor of hyperbilirubinemia in the following days for preterm 
neonates. Preterm neonates can have high bilirubin levels in the 
first few days of their lives. Therefore, daily TcB measure-
ment is important for early identification of hyperbilirubinemia, 
especially to prevent complications in certain more vulnerable 
preterm neonates. Close monitoring should be arranged for 
those who have TcB values higher than the cut-off values.
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mention include very preterm infants.  Perhaps the authors need to mean to say in their 
population but this needs to be clarified. 
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Each country does indeed need to develop their own criteria for diagnosis and treatment 
levels of hyperbilirubinemia based on risk in their environment, treatments available and 
other specifics related to their own country.  However, authors do need to tell us where 
there cutoffs for each group came from---are the in country normal, standard cutoffs for 
their hospital or region or how were they selected. 
 
2. 
Numbers too small to extrapolate widely to Indonesia or beyond. 
 
3. 
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4. 
Although not a major problem or limitation this article could be improved by having a native 
English speaker read and make minor edits throughout.
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If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
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1). Reviewer's comments: 
 
This study is an interesting study looking at the correlation between transcutaneous 
bilirubin (TcB) and serum bilirubin and the predictive value of subsequent clinically 
significant hyperbilirubinemia in neonates. However, there are some problems with the 
study that need to be addressed. 
  
The authors state that TcB has not been used in premature infants with the exception of 
late preterms. However, in a systematic review by Nager et al. most of the 22 articles they 
mention include very preterm infants.  Perhaps the authors need to mean to say in their 




Thank you for your comments. 
   
Yes, indeed you are right, thanks for your suggestion. What we meant here is similar with 
the study by Mayer (Mayer I, Gursoy T, Hayran M, Ovalı F. Value of twelfth-hour bilirubin 
level in predicting significant hyperbilirubinemia in preterms Infants. J Clin Med Res. 
2014;6(3):190–6) but they used TSB to predict significant hyperbilirubinemia later on. 
Practice in our hospital so far is using Kramer and few TSB measurement to start 
phototherapy. So, we give another alternative which is non-invasive, easy to use, and 
applicable in our setting in Indonesia.   
  
We added in our introduction as : 
  
In a systematic review by Nagar et al.16, most of 22 articles studied the accuracy of TcB to 
estimate TSB, and TcB could be used in clinical practice to reduce blood sampling. Some 
studies have used TcB to predict significant hyperbilirubinemia in subsequent days, but all 
of them recruited only late preterm and term neonates 5,17 . For preterm neonates, one 
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study was already conducted using TSB measurements at 6- 24 hours to predict 
hyperbilirubinemia in the following hours or days 4 . As far as the researchers know, there 
have been no previous studies using TcB to predict subsequent, significant 
hyperbilirubinemia for older preterm neonates. Therefore, this study aimed to use TcB to 
predict hyperbilirubinemia in preterm neonates to prevent complications since visual 
assessment is unreliable. 
 
 
2) Reviewer's comment: Each country does indeed need to develop their own criteria for 
diagnosis and treatment levels of hyperbilirubinemia based on risk in their environment, 
treatments available and other specifics related to their own country.  However, authors do 
need to tell us where there cutoffs for each group came from---are the in country normal, 
standard cutoffs for their hospital or region or how were they selected 
 
Author's response: 
Thank you for your comments. 
We added in our method à variables section as follows: 
  
The bilirubin level of each neonate was measured on the sternum by TcB (Dräger® Jaundice 
Meter 105) at 12 hours, 24 hours, and 72 hours with ±3 hours tolerance (the TcB 
measurement could be taken within three hours before/after the exact time). The TSB 
measurement was taken for each neonate at the age of three days or if the TcB bilirubin 
level was ≥5.76 (7-1.24)  mg/dL for Group I and TcB ≥8.76 (10-1.24) mg/dL for Group II and it 
had to be taken within six hours before or after the TcB measurement (assumption of TcB  
standard deviation being ±1.24 mg/dL). The TSB measurement also had to be taken if the 
TcB measurement showed abnormal results. Hyperbilirubinemia was defined as TSB ≥7 
mg/dL for preterm neonates with birth weights of 1000‒1500 g and TSB >10 mg/dL for 
preterm neonates with birth weights of 1501‒2000 g as suggested by the Kaplan et al., in 
Martin’s Neonatal-Perinatal Medicine (2011).21 
 
  
3). Reviewer's comment: 




This is the study limitation and has been addressed in discussion section. 
We added in the discussion section in the last paragraph: 
  
A limitation of the study was that it could not determine TcB cut-off values to predict 
hyperbilirubinemia at the age of 72 hours for preterm neonates weighing 1000–1500 grams 
due to a lack of subjects able to complete the study, since most had already developed 
significant hyperbilirubinemia by this time. 
 
4). Reviewer's comment: 
Rhesus of mothers and infants missing; G6PD status missing if not done state that. 
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Author's response: 
Dear Reviewer, 
Thank you for your comments. 
  
We even hardly measured Blood Group ABO and Rhesus of the mother and babies since the 
babies are not yellow. We have not used it as screening program. G6PD measurement is not 
affordable for our majority of citizen. We need to give consent first when the bilirubin is not 
yet decrease and rise again after intensive phototherapy, or there is sign of haemolysis  
  
Thank you for your suggestion. Indeed, this is also our limitation that we added in the 
discussion section on the last paragraph 
  
To the knowledge of the researchers, this was the first study conducted to predict 
significant hyperbilirubinemia in preterm neonates weighing 1000–2000 grams using TcB. A 
limitation of the study was that it could not determine TcB cut-off values to predict 
hyperbilirubinemia at the age of 72 hours for preterm neonates weighing 1000–1500 grams 
due to a lack of subjects able to complete the study, since most had already developed 
significant hyperbilirubinemia by this time. The mothers’ rhesus blood groups and the 
babies’ G6PD levels were not obtained. Hopefully, future similar studies will be able to 
recruit larger populations. 
 
 
5) Reviewer's comment: 
Although not a major problem or limitation this article could be improved by having a native 




Thank you for your comments 
  
We have already proofread this manuscript by Proofreading Service. 
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Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
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Italian Liver Foundation, Trieste, Italy 
This is an interesting study investigating in preterm neonates (PTNs) the predictive value of the 
bilirubin level assessed by transcutaneous technique (TcB) for hyperbilirubinemia (HB). 90 PTNs 
were and divided into two groups according to the weight (1500 g as diving value). Bilirubin was 
prospectively measured at different time points (12, 24, 48, and 72 h). Bilirubin level was 
confirmed by serum bilirubin measurement (TSB) if the TcB was “increased”. ROC curves were 
used to assess a 24 h TcB value predicting 48 and 72 h HB. Although the data may be of interest, 




The indication when TSB was measured is unclear and confusing. In the abstract it is stated 
that TSB was assessed before 72 h if TcB showed “abnormal results”. What does this mean? 




On what basis the TSB value of ≥ 7 mg/dL in group 1 and > 10 mg/dL HB in group 2 was 
selected? This needs to be scientifically substantiated. At what time this level was measured? 
 
2. 




Fig 1 shows that the time course of HB is different in the 2 groups being the bilirubin peak 
reached 24 h later in group 2. This difference accounts for the different TcB cutoff values. 
This needs to be considered and addressed in the discussion. 
 
4. 
How was the correlation between TcB and TSB at 72h? This information is important to 
assess the reliability of the two techniques (see also point #3). 
 
5. 
The abstract is inaccurate as data reported are different from those indicated in the text 
(see for example the lack of 48H values).
6. 
 
Is the work clearly and accurately presented and does it cite the current literature?
No
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
No
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Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
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I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 25 Jun 2020
Mahendra Tri Arif Sampurna, Dr. Soetomo Academic Teaching Hospital, Faculty of 
Medicine Universitas Airlangga, Surabaya, Indonesia 
1). Reviewer's Comment: The indication when TSB was measured is unclear and confusing. 
In the abstract it is stated that TSB was assessed before 72 h if TcB showed “abnormal 
results”. What does this mean? Detailed numerical values must be provided to allow to 




Thank you for your comments. 
  
We added in our method à variables section as follows: 
The bilirubin level of each neonate was measured on the sternum by TcB (Dräger® Jaundice 
Meter 105) at 12 hours, 24 hours, and 72 hours with ±3 hours tolerance (the TcB 
measurement could be taken within three hours before/after the exact time). The TSB 
measurement was taken for each neonate at the age of three days or if the TcB bilirubin 
level was ≥5.76 (7-1.24)  mg/dL for Group I and TcB ≥8.76 (10-1.24) mg/dL for Group II and it 
had to be taken within six hours before or after the TcB measurement (assumption of TcB  
standard deviation being ±1.24 mg/dL). The TSB measurement also had to be taken if the 
TcB measurement showed abnormal results. Hyperbilirubinemia was defined as TSB ≥7 
mg/dL for preterm neonates with birth weights of 1000‒1500 g and TSB >10 mg/dL for 
preterm neonates with birth weights of 1501‒2000 g as suggested by the Kaplan et al., in 
Martin’s Neonatal-Perinatal Medicine (2011). 
 
2). Reviewer's Comment: On what basis the TSB value of ≥ 7 mg/dL in group 1 and > 10 
mg/dL HB in group 2 was selected? This needs to be scientifically substantiated. At what time 




Thank you for your comments. 
   
The cut off 7 and 10 mg/dl are based on the recommendation of Martin Fanaroff (Reference 
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source: Kaplan M, Wong R, Sibley E, et al.: Neonatal Jaundice and Liver Disease. In: Martin’s 
Neonatal-Perinatal Medicine. 2011; 1443–90.) In this recommendation they use birth weight 
category regardless postnatal age in hours. 
  
3). Reviewer's comment: How TSB was measured? Were the lab values confirmed by 





Thank you for your comments. 
TSB measurements were performed by retrieving peripheral blood samples of each subject. 
Added in methods à variables section : 
Total serum bilirubin was measured in the central laboratory using SIEMENS Dimension® 
with a modified Doumas  22 reference method, which is a modification of the diazo method 
described by Jendrassik and Grof in 1938  23. Internal calibration was completed daily, with 
a quality control printout. The Indonesian External Quality Assurance Service performed 
external quality control. 
 
 
4). Reviewer's comment: Fig 1 shows that the time course of HB is different in the 2 groups 
being the bilirubin peak reached 24 h later in group 2. This difference accounts for the 




Thank you for the comment. 
 
We added in the discussion: 
 
It shows that that higher birth weight has opportunity to be hyperbilirubinemia later than 
the lower birthweight. The lower birthweight has lower threshold bilirubin, because they 
have higher chance to become encephalopathy in lower bilirubin level (high risk infants). 
The younger gestational age and lower birth weight, lead to a higher prevalence of infants 
developing hyperbilirubinemia. It is a result of excessive neonatal red cell hepatic and 
immaturity of the gastrointestinal system. Prematurely delivered infants have a likelihood of 
slower maturation of hepatic bilirubin uptake and conjugation. 
 
5). Reviewer's comment: How was the correlation between TcB and TSB at 72h? This 




Thank you for your comments. 
We actually did not assess the correlation between TcB and TSB at 72 hours of age. We 
would like to mention our reasons why we did not perform the assessment as the 
followings:
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We were not specifically aiming at performing diagnostic test;1. 
We only discovered fewer observed subjects who had reached observation at 72 
hours of age thus the sample size at that age was not abundant in number. Most of 
the infants underwent phototherapy before 72 hours (group 1). Those infants were 
excluded from the study for further analysis.
2. 
6) Reviewer's Comment: The abstract is inaccurate as data reported are different from 





Thank you for noticing. We adapted our abstract accordingly 
  
We also found that there was an unsuitable data between those mentioned in the study 
abstract and the ones in figures. However, we would like to inform that the proportional 
data provided in the study abstract is correct already meanwhile the ones in figures were 
attained by integrating the data percentages. Therefore, we are going to amend and adjust 
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